Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02428712 · ClinicalTrials.gov registry record · Phase 1
A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors
A Phase 1 study, sponsored by Fore Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 113
- Enrollment target
NCT02428712 is a Phase 1 study that has completed, run by Fore Biotherapeutics. The registered enrollment target is 113 participants.
The verdict
NCT02428712, a Phase 1 study, has completed, sponsored by Fore Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 113 participants
- Enrollment target
Study Summary
The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of FORE8394.
Interventions
- DRUG FORE8394
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2015-04 |
| Est. Completion | 2024-07-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02428712
The ClinicalTrials.gov registry entry for NCT02428712 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fore Biotherapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FORE8394 is the first listed.
NCT02428712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02428712 about?
NCT02428712 is a clinical study titled "A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors". The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of FORE8394.
What is the current status of trial NCT02428712?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 113 participants. The study started on 2015-04. Estimated completion is 2024-07-12.
What interventions are being tested in trial NCT02428712?
The interventions under investigation include: FORE8394 (DRUG).
Who is sponsoring clinical trial NCT02428712?
This trial is sponsored by Fore Biotherapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.